MedAvante Research Shows Improved Psychiatric Assessments in Clinical Trials 

Virgil eCOA Reduces HAM-D Item Scoring Errors Up To 70%

Scottsdale AZ (June 1, 2016) – MedAvante, Inc., the leading global scientific clinical data services company, today presented research at the 2016 American Society of Clinical Psychopharmacology (ASCP) meeting quantifying error reduction in actual clinical trials of treatments for major depressive disorder (MDD). The new study compares traditional paper-based assessments in clinical trials with the Virgil® Investigative Study Platform, which uses a digital tablet to administer and score clinical outcome assessments (eCOA) and capture source data (eSource).

MedAvante Presents Research On Electronic Clinical Outcome Assessments

Dr. Nigel Brown to Serve as Senior Adviser to MedAvante

MedAvante Releases New Software for the Virgil® Investigative Study Platform

MedAvante to Present at Cavendish Global Health Impact Forum